Is massive scale proteomics causing a paradigm shift in biomarker discovery?
ABSTRACT
In this 45-minute talk, Dr. Stefánsson will discuss the largest population proteomics study ever performed to help provide more insight on disease and health outcomes. This collaborative research assembled expertise from deCODE Genetics and SomaLogic to combine the study of genetic and protein diversity to characterize disease biomarkers in the human population. The data from this type of proteomic study will inform drug discovery and development as well as improvements in health management. You will learn about:
- The high-throughput technologies that made this study possible
- The application of population proteomics in diagnosis and management of common and rare diseases
Dr. Kári Stefánsson
CEO, deCode Genetics
Kári Stefánsson is an Icelandic neurologist and founder and CEO of Reykjavik-based biopharmaceutical company deCODE genetics. In Iceland he has pioneered the use of population-scale genetics to understand variation in the sequence of the human genome.
More webinars
WebinarPathways to Digital Health: AI and Omics in Rheumatoid Arthritis
Explore how groundbreaking proteomic research is transforming our understanding of rheumatoid arthritis (RA). In this on-demand webinar, Allan Stensballe, PhD, shares new insights into the molecular landscape of RA-affected synovial tissue, revealing how autoantibodies and protein signatures may hold the key to more precise personalized therapies.
WebinarUsing Antibody Profiling to Identify Novel Diagnostic Biomarkers
Current cancer screening methods often lead to false positives, false negatives and invasive biopsies that lack prognostic insights. Emerging research suggests that cancer-specific IgM and IgG antibodies – produced by B cells upon recognizing malignant cells – could serve as stable, easily measurable blood biomarkers for detecting and monitoring high-incidence cancers like melanoma and breast, prostate, bowel, lung and pancreatic cancer. This approach has the potential to improve early diagnosis, reduce uncertainty and enhance treatment planning.
WebinarLinking the plasma proteome to echocardiographic parameters in patients with chronic heart failure
Recent advancements in proteomic profiling have unlocked new possibilities for understanding the complex mechanisms that drive heart failure. Measuring thousands of proteins simultaneously makes it possible to capture a comprehensive overview of the patient's health state and investigate underlying disease progression at a subclinical level.